Baxdrostat / Lorundrostat

Drug Overview

Baxdrostat and Lorundrostat represent a groundbreaking new frontier in the Nephrology and cardiovascular specialties. Classified as Aldosterone Synthase Inhibitors (ASIs), these highly specific agents function as a novel Targeted Therapy for patients with treatment-resistant hypertension (TRH) and chronic kidney disease (CKD). Unlike traditional medications that block the effects of aldosterone at the receptor level, these innovative molecules are designed to halt the endogenous production of the hormone altogether, effectively mitigating its pro-fibrotic and hypertensive effects on the kidneys and cardiovascular system.Baxdrostat / Lorundrostat

• Generic Names: Baxdrostat (formerly CIN-107), Lorundrostat (formerly MLS-101)
• US Brand Names: Currently in late-stage clinical development; commercial brand names are pending final regulatory approval.
• Route of Administration: Oral (Tablets/Capsules)
• FDA Approval Status: As of early 2026, Baxdrostat and Lorundrostat are classified as investigational Targeted Therapies undergoing advanced Phase 3 clinical trials. While not yet universally available for standard prescription, they have received Fast Track or equivalent regulatory designations due to their potential to address significant unmet medical needs in resistant hypertension and renal fibrosis.
  
  Review Aldosterone Synthase Inhibitors (Baxdrostat). It prevents resistant HT and renal fibrosis by cutting off aldosterone production. Read clinical guide. Baxdrostat / Lorundrostat

What Is It and How Does It Work? (Mechanism of Action)

To understand how Baxdrostat and Lorundrostat function, one must look at the renin-angiotensin-aldosterone system (RAAS), a critical regulator of blood pressure and fluid balance. Chronic overproduction of aldosterone drives sodium retention, severe hypertension, and direct structural damage to the renal architecture (fibrosis).

At the molecular and enzymatic level, these drugs act as highly selective inhibitors:

• Enzyme Target (CYP11B2): Aldosterone is synthesized in the adrenal cortex by an enzyme called aldosterone synthase (cytochrome P450 11B2, or CYP11B2). Baxdrostat and Lorundrostat competitively bind to and inhibit this specific enzyme, cutting off aldosterone production directly at the source.
• High Selectivity Mechanism: The fundamental challenge in developing this Targeted Therapy was the 93% genetic sequence similarity between CYP11B2 and CYP11B1 (the enzyme responsible for synthesizing cortisol). First-generation inhibitors inadvertently blocked cortisol, leading to dangerous adrenal insufficiency. Baxdrostat and Lorundrostat possess unique molecular structures that achieve  >100-fold  to  >300-fold  selectivity for CYP11B2 over CYP11B1, effectively suppressing aldosterone without blunting the crucial cortisol stress response.
• Overcoming Receptor Upregulation: Traditional mineralocorticoid receptor antagonists (MRAs like spironolactone) block the aldosterone receptor but cause a reactive spike in circulating aldosterone levels. By inhibiting synthesis entirely, ASIs prevent the hormone from interacting with non-genomic receptors that contribute to inflammation and renal fibrosis.

FDA-Approved Clinical Indications

(Note: As these agents are currently in late-stage Phase 3 clinical development, the following represent their primary investigational targets and anticipated clinical indications).

• Primary Indication: Prevents resistant hypertension (TRH) and renal fibrosis by cutting off aldosterone production directly at the source.
• Other Investigational / Anticipated Uses:
  • Chronic Kidney Disease (CKD): Reduction of proteinuria and prevention of progressive glomerulosclerosis in patients with proteinuric CKD.
  • Primary Aldosteronism: Medical management of autonomous aldosterone overproduction in patients who are not candidates for adrenal surgery.
  • Heart Failure with Preserved Ejection Fraction (HFpEF): To reduce systemic vascular resistance and myocardial fibrosis.

Dosage and Administration Protocols

Because these medications are still utilized primarily within clinical trial frameworks (such as the BrigHtn, HALO, and Target-HTN trials), the dosing parameters below reflect current late-stage study protocols.

Dose Adjustments

• Renal Insufficiency: Renal impairment (eGFR < 60 mL/min/1.73m²) increases the risk of hyperkalemia. Patients with moderate-to-severe CKD may require initiation at the lowest possible dose (e.g., 0.5 mg Baxdrostat or 12.5 mg Lorundrostat) with rigorous serum potassium monitoring.
• Hepatic Insufficiency: Pharmacokinetic data is continually emerging; however, mild to moderate hepatic impairment is not expected to require severe dose restrictions.
• Concurrent RAAS Inhibitors: Concomitant use with ACE inhibitors, ARBs, or standard MRAs dramatically increases the risk of elevated potassium and requires specialized dose titration.

Clinical Efficacy and Research Results

Clinical trial data published between 2022 and 2026 has demonstrated robust efficacy for this new class of Targeted Therapy, particularly for patients whose blood pressure remains uncontrolled despite taking three or more standard antihypertensives.

• Blood Pressure Reduction: In the Phase 2 BrigHtn trial, patients receiving 2 mg of Baxdrostat achieved a placebo-corrected reduction in systolic blood pressure of exactly 11.0 mmHg at 12 weeks. Similarly, the Target-HTN trial demonstrated that Lorundrostat (50 mg) reduced systolic blood pressure by 9.6 mmHg compared to placebo.
• Aldosterone Suppression: Biomarker analyses from these trials confirmed significant reductions in serum and urinary aldosterone levels, validating the targeted mechanism of action without compromising cortisol pathways.
• Renal Protection and Proteinuria: Long-term follow-up data and ongoing Phase 3 trials in CKD populations indicate a clinically significant decrease in the Urine Albumin-to-Creatinine Ratio (UACR), suggesting that suppressing aldosterone synthesis slows the progression of renal interstitial fibrosis.

Safety Profile and Side Effects

Black Box Warning: None currently assigned, as the drugs are under investigational status. However, rigorous monitoring parameters are established in all trial protocols.

Common Side Effects (>10%)

• Hyperkalemia: Elevated serum potassium levels due to the reduction of aldosterone-mediated potassium excretion in the kidneys.
• Mild hypotension (low blood pressure) and dizziness.
• Hyponatremia (mild, usually asymptomatic reductions in serum sodium).

Serious Adverse Events

• Severe Hyperkalemia: Potassium levels  \ge  6.0 mmol/L, which can precipitate life-threatening cardiac arrhythmias.
• Adrenal Insufficiency (Theoretical): Although these agents are highly selective, there is a remote risk of blunted cortisol response during acute physiological stress or severe illness.

Management Strategies

• Potassium Monitoring Protocol: Serum potassium must be checked within 1 to 2 weeks of initiating therapy or altering the dose. If potassium exceeds 5.5 mmol/L, the dose must be reduced or temporarily held. Concurrent use of novel potassium binders (e.g., patiromer) may be utilized to allow patients to remain on the therapy.
• Cortisol Monitoring: Routine monitoring of morning cortisol is part of the clinical trial safety protocol to ensure the CYP11B1 enzyme remains uninhibited.

Research Areas

By directly halting the production of aldosterone, Baxdrostat and Lorundrostat exhibit profound anti-fibrotic properties within the renal parenchyma. In the advancing field of regenerative nephrology, controlling tissue fibrosis is paramount. Chronic scarring creates a hostile extracellular matrix that prevents cellular regeneration. Current preclinical models (2024–2026) are exploring how establishing a “fibrosis-free” vascular and tubular niche via Aldosterone Synthase Inhibitors can serve as a vital pre-conditioning step. This pharmacological preparation aims to improve the homing, survival, and integration of systemically infused mesenchymal stem cells (MSCs) or other advanced cellular therapies designed to repair chronic kidney injury.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Comprehensive Metabolic Panel (CMP): Baseline eGFR, serum potassium (must typically be  \le  4.5 mmol/L prior to starting), and sodium levels.
• Endocrine Panel: Baseline plasma renin activity (PRA), serum aldosterone, and a morning serum cortisol test.
• Blood Pressure Mapping: 24-hour ambulatory blood pressure monitoring (ABPM) to verify true resistant hypertension.

Precautions During Treatment

• Dietary Vigilance: Patients must be educated to avoid high-potassium foods (e.g., bananas, avocados, potatoes) and strictly avoid over-the-counter salt substitutes, which are often made of pure potassium chloride.
• Sick Day Rules: During acute illnesses that cause severe dehydration (vomiting, diarrhea), the medication may need to be temporarily paused to prevent acute kidney injury and potassium spikes.

Do’s and Don’ts

• DO take the medication at the same time every day to maintain steady suppression of the target enzyme.
• DO attend all scheduled laboratory blood draws; managing your potassium levels is the most critical safety requirement of this medication.
• DO monitor your blood pressure at home and keep a log for your physician.
• DON’T start taking any new supplements, especially herbal remedies or NSAIDs (like ibuprofen), without consulting your nephrologist, as they can suddenly decrease kidney function and spike your potassium.
• DON’T stop taking your other prescribed blood pressure medications unless explicitly directed by your specialist; this drug is designed to work alongside them.

Legal Disclaimer

The information provided in this medical guide is for educational and informational purposes only and does not constitute medical advice. Baxdrostat and Lorundrostat are currently investigational medications and are not yet fully approved by the FDA or EMA for general prescription use outside of clinical trials. Treatment protocols, safety data, and indications are subject to change based on pending regulatory reviews. Patients should always consult with a licensed healthcare professional, nephrologist, or cardiologist regarding diagnosis, clinical trial eligibility, and the appropriateness of specific targeted therapies for their individual health profiles.